Company Research Report: CISTIM Leuven vzw
Company Overview
Name
CISTIM Leuven vzw
Mission
CISTIM Leuven is dedicated to bridging the gap between innovative biomedical research from academic institutes or biotechs and the pharmaceutical industry, with a primary focus on drug discovery that addresses critical medical needs.
Founding and Founders
CISTIM Leuven was founded in 2007 by KU Leuven (University of Leuven).
Key People in the Company
- Dr. Patrick Chaltin: Managing Director. Co-founder and key leader at CISTIM since its inception.
- Dr. Arnaud Marchand: Executive Director Medicinal Chemistry.
- Stefaan Allemeersch: Executive Director Business Development.
- Dr. Matthias Versele: Executive Director of Drug Discovery Biology.
Headquarters
Bioincubator 2, Gaston Geenslaan 2, 3001 Leuven, Belgium.
Number of Employees
Approximately 45 dedicated team members.
Revenue
No information is available.
Known For
CISTIM is known for its capabilities in early drug discovery and its collaborative efforts with CD3 to deliver potential drug candidates to the pharma and biotech industries.
Products
Offered Products
CISTIM focuses on discovering new medicines, particularly small molecules and biologics, such as therapeutic antibodies.
High-level Description of the Product
CISTIM's work involves collaborative drug discovery projects ranging from understanding novel biological insights to the development of preclinical candidates.
Key Features
CISTIM offers expertise in:
- Assay development and optimization
- High throughput screening
- High-quality diverse compound libraries
- In silico design, modelling, screening, and AI machine learning-based hit identification
- Medicinal and analytical chemistry
- Organic synthesis and ADME-Tox evaluations
- PK and in vivo efficacy evaluations
- PD biomarker development and analysis
- Antibody discovery
- Full project coordination, follow-up, and IP rights protection
Recent Developments
New Products Launched
No specific information on new product launches is available.
New Features Added to Existing Products
No information is available.
New Partnerships
- SandboxAQ Collaboration (November 29, 2024): CD3 and the KU Leuven Lab of Cellular Transport Systems joined forces with SandboxAQ to develop new therapeutics for Parkinson’s Disease.
- Open Philanthropy Funding (May 03, 2024): Prof. Lieve Naesens and CD3 acquired substantial funding to prepare against influenza pandemics.
Other Notable Developments
- Opening of Belgian VirusBank Platform (October 26, 2023).
- Significant Investment by CD3 (October 19, 2023): CD3 raised 70.5 million euros for its fourth fund, increasing its total capital managed to 154.5 million euros.
- Collaborations with companies like Janssen and Gilead Sciences to advance antiviral projects.
Conclusion
CISTIM Leuven vzw is a pivotal player in the realm of drug discovery, uniquely positioned to drive the development of tomorrow's medicines through partnerships and innovative research. Operating from its headquarters in Leuven, Belgium, it stands alongside CD3 as a beacon for transforming promising scientific endeavors into tangible therapeutic solutions.
